Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,284 across all filing types
Latest filing 2026-05-12 Remuneration Information
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
董事、高级管理人员薪酬管理办法（2026年5月修订）
Remuneration Information Classification · 90% confidence The document is a detailed policy (“办法”) outlining the structure, principles, components, calculation methods, and oversight of remuneration for the company’s board members and senior management. It does not present financial results, voting outcomes, or report publication notices, nor is it a regulatory certification or earnings release. Instead, it specifically details executive and director compensation governance, matching the definition of Remuneration Information (Code: DEF 14A).
2026-05-12 Chinese
关于参加2026年吉林辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 80% confidence The document is a short announcement by the company’s board regarding its participation in an upcoming online investor reception day. It does not contain financial statements, voting results, a proxy statement, or detailed investor presentation content, nor does it announce publication of a report. It is a general regulatory/IR announcement, fitting the fallback category for miscellaneous regulatory filings.
2026-05-12 Chinese
北京大成（长春）律师事务所关于长春高新技术产业（集团）股份有限公司2025年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter issued by Beijing Dacheng (Changchun) law firm regarding the legality of the 2025 annual shareholders’ meeting procedures, attendee qualifications, voting processes, and results. It is not the actual AGM presentation materials (AGM-R), proxy solicitation (PSI), or a straightforward voting results announcement (DVA) but a compliance/legal opinion required under securities law, making it a general regulatory disclosure. It does not contain substantive financial statements or serve as an annual or interim report. Therefore, it falls under the catch-all Regulatory Filings category (RNS).
2026-05-12 Chinese
关于子公司伏欣奇拜单抗注射液境内生产药品注册临床试验申请获得批准的公告
Regulatory Filings Classification · 85% confidence The document is a corporate announcement describing the subsidiary’s approval for clinical trial registration of a drug injection. It contains no financial statements, no quarterly or annual reporting data, no proxy or shareholder vote information, and no executive changes. Instead, it is a general regulatory disclosure of operational progress (drug approval) required by authorities. This fits the “Regulatory Filings” (RNS) category as a miscellaneous compliance announcement that does not fall under any more specific category.
2026-05-12 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 87% confidence The document is an official announcement of the resolutions and voting results from the 2025 annual shareholders’ meeting, detailing attendance, vote counts, proposal outcomes, and legal opinions. It does not present financial data itself nor is it a notice of report publication. This matches “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2026-05-12 Chinese
关于子公司GenSci161注射液境内生产药品注册临床试验申请获得批准的公告
Regulatory Filings
2026-04-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.